$DRIO

DarioHealth Corp. (NASDAQ: DRIO) said it expanded its provider-backed cardiometabolic platform with two new programs, Dario Women and Dario Sleep. The company expects rollouts to Fortune 500 clients in Fall 2026 and recurring revenue per engaged member per month to start in Q4 2026, with provider-backed care revenue expected end-2026 into early 2027.

DarioHealth Corp. (NASDAQ: DRIO) launched an Integrated GLP-1 Program combining its AI chronic care platform with provider-backed clinical care from Beluga Health. The offering adds licensed evaluation, prescribing of FDA-approved GLP-1s, and ongoing oversight in one platform. Availability is expected in Fall 2026, with revenue starting late 2026 and ramping through 2027.

Matheis Dennis purchased 14,430 shares of DarioHealth Corp. (DRIO) at $6.93 on 2026-07-23.

A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.

DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 tm2621105d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 22, 2026, between DarioHealth Corp., a Delaware corporation (the “ Company ”), and the purchasers identified on the

DarioHealth Corp. (NASDAQ: DRIO) said a Fortune 50 employer selected its AI-powered digital cardiometabolic care platform for diabetes and/or hypertension for over 100,000 eligible employees. The program is expected to launch in Fall 2026, with annual recurring revenue starting by year-end and increasing through 2027, according to the company.

DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001533998 0001533998 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date

DarioHealth Corp (NASDAQ:DRIO) shares rose 5.7% after an expanded agreement with one of the five largest U.S. health insurers. The insurer will add Dario’s AI hypertension solution to its existing behavioral health offering, expanding the addressable population. Revenue from the expanded program is expected in 2026, with greater impact in 2027+.

DarioHealth Corp. (NASDAQ: DRIO) said a major U.S. health insurer extended and expanded its agreement, adding Dario’s hypertension solution after success with behavioral health. The insurer’s cardiometabolic rollout is expected to contribute revenue in 2026, with greater impact in 2027+. Dario said this is its third payer expansion beyond an initial condition.

DarioHealth Corp. (DRIO) has filed an S-3 shelf registration statement to offer up to $100 million in various securities, including common stock, preferred stock, warrants, and units. This administrative filing allows the company to access capital markets "from time to time" to fund commercial activities, R&D, M&A, and general working capital. As of March 19, 2026, DarioHealth reported 7,300,406 shares of common stock outstanding.